The Daily Toke

March 22, 2026

Ohio's sweeping crackdown on THC products took effect Friday after activists failed to gather enough signatures to block the controversial law through a referendum. Senate Bill 56, signed by Gov. Mike DeWine in December, bans THC beverages at bars and breweries, restricts hemp-derived cannabis products to 0.4 milligrams of THC per container, and eliminates legal protections for marijuana consumers—meaning Ohioans can now lose unemployment benefits, organ transplants, and parenting rights based solely on cannabis use. The law directly contradicts the 57% of Ohio voters who approved recreational marijuana legalization in 2023. Ohioans for Cannabis Choice fell short of the nearly 250,000 signatures needed in just one month, relying primarily on volunteer businesses including breweries that now face legal uncertainty. A lawsuit filed by Cincinnati breweries challenging DeWine's veto of a provision allowing THC beverage sales through 2026 is currently pending before the Ohio Supreme Court.

Meanwhile, across state lines, the cannabis regulatory landscape is fragmenting rapidly as states race to align with incoming federal restrictions. Pennsylvania's Senate Law and Justice Committee voted 10-1 to amend its Cannabis Control Board bill to mirror new federal hemp definitions before a November deadline when tighter restrictions take effect. Senator Dan Laughlin, the Republican sponsor, framed the move as necessary to "close loopholes" and prepare infrastructure—a pragmatic play that simultaneously advances his separate bipartisan legalization bill. 💰 MONEY MOVES The hemp-derived THC market represents $28.4 billion in annual sales, and Rep. James Comer (R-KY), chair of the House Oversight Committee, is actively urging Congress to delay federal restrictions that would effectively eradicate the category. Louisiana lawmakers introduced a limited recreational cannabis pilot program running through 2030, but the proposal faces criticism from state Attorney General Liz Murrill and local entrepreneurs who argue it simply entrenches existing medical operators' monopoly rather than creating genuine legalization.

Virginia is moving faster, with lawmakers approving legislation to launch a regulated adult-use retail market five years after decriminalizing possession without creating a legal way to purchase. The Virginia Cannabis Control Authority unveiled new licensing simplification measures, social equity programs for minority-owned businesses, and strict product testing guidelines—🚀 THIS IS COOL a regulatory framework designed to prevent the uncontrolled hemp product proliferation that triggered crackdowns in Ohio and Pennsylvania. Tennessee Democrats filed the "Pot for Potholes Act" for the second consecutive year, explicitly tying marijuana legalization revenue to infrastructure spending in hopes of attracting fiscal conservatives and rural lawmakers skeptical of cannabis policy on moral grounds alone.

The federal pressure is unmistakable. The pending November 2026 federal THC restrictions under the new hemp definition would compress the entire intoxicating hemp market—delta-8, delta-10, THC-O gummies, and infused beverages—into regulatory categories so tight that most existing products wouldn't qualify. States are now choosing between proactive regulation (Pennsylvania, Virginia, Louisiana's pilot) and reactive prohibition (Ohio). 🤔 THINK ABOUT IT Ohio voters legalized cannabis in 2023, then elected representatives who restricted it in 2026. Meanwhile, hemp products—technically legal federally until November—are being banned in anticipation of rules that don't exist yet. And all this regulatory friction occurs while prescription opioids kill over 16,000 Americans annually and alcohol kills 95,000, neither facing the legal demolition cannabis is receiving in states where voters explicitly approved it.

March 22, 2026

Across the country, states are drawing sharp lines around intoxicating hemp products in a coordinated regulatory push that reflects deeper fractures within Republican leadership on cannabis policy. Ohio's ban took effect on March 20, immediately shutting down sales of THC and CBD beverages while capping delta-9 THC in extracts at 70% and flower at 35%—a move that failed to trigger a public referendum after cannabis advocacy groups missed a March 19 signature deadline with over 248,000 valid signatures needed from 44 counties. On the same day, South Carolina's Senate passed a compromise regulation that keeps low-dose hemp gummies and drinks legal but restricts them to liquor stores and adults 21 and over, after two weeks of fractious debate saw hard-right GOP members clash with more moderate Republicans and Democrats over whether to ban the products outright or regulate them.

The coordinated state action mirrors a federal deadline: a pending change to the federal hemp definition is set to take effect in November 2026, effectively eradicating the hemp-derived THC market as it currently exists. Pennsylvania Senate Republicans, sensing this shift, amended cannabis regulation legislation in March to preemptively align state law with the coming federal change, banning most hemp THC products through Senate Bill 49. Sen. Dan Laughlin (R), the bill's sponsor, framed the move as necessary to "close loopholes that allowed intoxicating hemp products to flood the marketplace with little oversight"—language that reflects a broader narrative among conservative lawmakers that the hemp market, which exploded after the 2018 Farm Bill legalized hemp at 0.3% delta-9 THC by dry weight, has spiraled into an unregulated "Wild West."

💰 MONEY MOVES The stakes are substantial: in Ohio alone, advocates estimate 6,000 hemp businesses could shut down, displacing thousands of workers. In South Carolina, the compromise reflects genuine fear among small-business operators and hospitality venues that an outright ban would destroy livelihoods—yet Republican Party leadership went on record supporting a total statewide ban anyway. Meanwhile, Rhode Island regulators backed a ban on THC drinks at venues with liquor licenses after over 100 bars and restaurants secured licenses to sell the products between August 2024 and July 2025, a period when the state's former Office of Cannabis Regulation was issuing approvals despite regulations technically prohibiting the combination of THC with alcohol. The hospitality association called the regulatory recommendation "targeting," arguing industry members would follow the law if given clear rules—a tension between enforcement skepticism and business survival that appears nowhere near resolution.

🤔 THINK ABOUT IT What's notable here is not the regulatory impulse itself, but the political contradiction underlying it. Republicans across these states are imposing strict age limits, potency caps, and sales restrictions on hemp products—a zero-recorded-overdose substance—while accepting campaign contributions from alcohol, tobacco, and pharmaceutical industries whose products kill tens of thousands of Americans annually. If child safety were genuinely the priority, one might expect equal or greater regulatory energy applied to alcohol (the #1 drug-related killer of teenagers) and prescription opioids (which killed over 16,000 Americans in recent years). Instead, the pattern shows a selective moral panic: hemp is dangerous and must be restricted, while products with documented body counts remain legal and marketed freely.

Congressional researchers added another layer of uncertainty in March when they updated their analysis of marijuana rescheduling and federal hemp policy, notably removing language predicting it was "likely" the DEA would move cannabis from Schedule I to Schedule III. The new version says DOJ "may" reschedule—a significant softening that reflects continued gridlock. Federal agencies under the Biden administration had recommended rescheduling, and Trump issued an executive order directing the process in December, yet no action materialized. Even if rescheduling happens, researchers emphasized it would not bring state-legal recreational cannabis into federal compliance with the Controlled Substances Act without additional legislation. The legal architecture remains fractured: states moving to ban hemp products while federal hemp policy is in flux, all while a 50-year-old Schedule I classification persists despite its own commission (the Shafer Commission in 1970) recommending decriminalization.

What emerges is a patchwork response to a problem that arguably didn't require state-level bans. The hemp market, born from federal legalization in 2018, thrived because there was a legal gray area and genuine consumer demand. States are now closing that gap ahead of federal action—but the process reveals deep disagreement about whether regulation or prohibition serves public health better. Ohio chose prohibition. South Carolina chose compromise regulation. Pennsylvania is aligning with federal winds. Rhode Island is caught between industry pushback and regulator concerns. For consumers, workers, and small-business owners in these states, the result is regulatory whiplash masquerading as public health policy—all while the substances proven to kill Americans remain legally unrestricted and politically untouchable.

March 22, 2026

Researchers have published the largest-ever systematic review of medicinal cannabis for mental health, and the findings are stark: there is virtually no high-quality evidence that cannabis treats depression, anxiety, or PTSD—the three conditions patients most commonly cite when seeking prescriptions. The analysis, published in *The Lancet Psychiatry* and led by Dr. Jack Wilson at the University of Sydney's Matilda Centre, examined 54 randomized controlled trials spanning 45 years and found no meaningful benefit for these conditions, nor for psychotic disorders, anorexia, or opioid use disorder. The research underscores a troubling reality: public adoption of medicinal cannabis has far outpaced the science supporting it.

💰 MONEY MOVES The timing is significant. Australia has seen medicinal cannabis sales quadruple since 2022, with over 700,000 Australians now using cannabis products for health purposes, yet the majority of products prescribed remain unregistered with the Therapeutic Goods Administration and have never undergone rigorous testing. More than one million prescription approvals have been granted in Australia alone over the past four years, often for mental health conditions that the new evidence suggests cannabis cannot effectively treat. Dr. Wilson warned that routine use of medicinal cannabis could be "doing more harm than good" by worsening mental health outcomes, increasing risk of psychotic symptoms, developing cannabis use disorder, and delaying access to proven treatments.

The research did identify one promising area: medicinal cannabis—typically an oral oil-based combination of CBD and THC—showed potential for reducing cannabis use among people with cannabis use disorder itself, likely by reducing cravings. There was also low-quality evidence suggesting possible benefits for autism, insomnia, and Tourette's syndrome, though Wilson cautioned these findings warrant caution and robust medical support. Conditions like epilepsy-related seizures, multiple sclerosis spasticity, and certain pain types showed more established evidence, but mental health disorders decisively did not. The researchers were clear: without robust evidence, routine use of medicinal cannabis for psychiatric conditions "should be rarely justified."

The funding and research infrastructure gap explains part of why the evidence base remains so thin. For over 50 years, cannabis has held Schedule I status with the DEA, which has made large-scale, well-controlled clinical trials extraordinarily difficult to fund and conduct. 🤔 THINK ABOUT IT We've spent decades restricting research on a plant that has zero recorded overdose deaths while simultaneously allowing unrestricted marketing of alcohol—which kills approximately 95,000 Americans annually—and prescription opioids, which kill over 16,000 per year. That disparity in research investment, regulatory scrutiny, and public messaging speaks volumes about how drug policy shapes science rather than the other way around. Even as multiple U.S. states legalized medical and recreational cannabis, that shift did not trigger the large-scale investment in high-quality clinical research that would typically accompany a widely-used therapeutic agent.

What happens now matters. 🚀 THIS IS COOL The research itself represents genuine scientific rigor—the most comprehensive systematic review ever conducted on this question. But its conclusions will likely clash with existing prescription patterns and patient expectations in markets where cannabis has already been normalized for mental health use. Practitioners face a decision: do they continue prescribing based on patient demand and anecdotal reports, or do they pivot toward the evidence-based position Dr. Wilson articulated—that absent robust proof, medical cannabis should rarely be used for depression, anxiety, and PTSD? The study doesn't argue cannabis is harmful for everyone or that research should stop; it argues clearly that the evidence simply isn't there yet, and that continuing to prescribe it for these conditions while better-studied alternatives exist represents a gap between promise and proof that patients deserve to understand.

March 22, 2026

Texas hemp businesses face a seismic shift on March 31 when new state regulations take effect that will effectively ban smokable cannabis products, threatening what industry operators say represents 50 to 70 percent of their sales. The Texas Department of State Health Services finalized rules in early March that change how the state calculates legal THC levels by now including THCA—a non-intoxicating compound that converts to delta-9 THC when heated—in the total THC measurement. This definitional change, combined with licensing fee increases of roughly 3,000 percent (from $155 to $5,000 annually for retailers), puts thousands of small businesses in an impossible position with less than two weeks to adapt.

Jacob Warner, co-owner of Alamo Bud Co. in San Antonio, told reporters that 70 percent of his store's inventory will be illegal after the deadline. Jacqueline Walji, who owns Mellow Monkey with her husband, said THCA flower and concentrates make up about half her business—and she's already noticed competitors shutting down preemptively. 💰 MONEY MOVES For Full Spectrum in San Angelo, the loss of THCA products that represent 35 to 50 percent of sales, paired with the new $5,000 licensing fee (up from $155), creates a math problem the store's managing partner Allen Kirk describes as potentially unsustainable. The regulations also mandate stricter age verification, mandatory product testing, enhanced packaging requirements, and detailed recordkeeping for manufacturers, distributors, and retailers across Texas's roughly 8,000 registered hemp businesses.

The speed of implementation has alarmed industry attorneys and policy experts. Heather Fazio, director of the Texas Cannabis Policy Center, noted that businesses are being asked to remove 50 to 70 percent of their inventory in just four weeks—without a grace period to clear stock or adjust operations. Dallas attorney Chelsie Spencer, who helps hemp retailers stay compliant with state and federal law, expressed concern that confusion around the new rules could invite increased law enforcement action. 🤔 THINK ABOUT IT Since August 2024, local and federal agencies have raided more than 15 hemp businesses across Texas, seizing products and cash that many retailers haven't recovered despite not being convicted of crimes. Veterans relying on smokable THCA products for PTSD and chronic pain also face uncertainty; Kirk warned that removing intoxicating hemp from legal markets could push customers toward unregulated street alternatives with no safety oversight.

The Texas restrictions come as Ohio is implementing its own hemp crackdown following the failure of a referendum effort by Ohioans for Cannabis Choice to block Senate Bill 56. That law bans THC beverages, restricts hemp-derived products, and eliminates legal protections for marijuana consumers—meaning they can lose unemployment benefits, organ transplant eligibility, and parenting time based solely on cannabis use.

Gov. Greg Abbott vetoed an outright cannabis ban during the 2025 legislative session and instead ordered state agencies to develop stricter regulations. Those regulations are now in effect, creating a de facto ban of smokable products through definitional changes rather than explicit prohibition. Texas Hemp Business Council and local retailers argue the regulations weren't designed with any transition period—a sharp contrast to how most industries handle major rule changes. As of March 31, Texas will have effectively eliminated one of the largest legal cannabis markets in the country, and thousands of small businesses will either comply by removing products or face potential raids and asset seizure like the 15-plus businesses law enforcement has targeted since mid-2024.